

## TABLE OF CONTENTS

	Page
<b>ACKNOWLEDGEMENTS</b>	iii
<b>ABSTRACT (ENGLISH)</b>	v
<b>ABSTRACT (THAI)</b>	vii
<b>TABLE OF CONTENTS</b>	x
<b>LIST OF TABLES</b>	xv
<b>LIST OF FIGURES</b>	xvi
<b>ABBREVIATIONS AND SYMBOLS</b>	xix
<b>CHAPTER 1 INTRODUCTION</b>	
1.1 Background and significance	1
1.2 Aims of the study	4
<b>CHAPTER 2 LITERATURE REVIEWS</b>	
2.1 Biology of HIV	5
2.1.1 Classification and morphology	5
2.1.2 Genomic structure	7
2.1.3 Viral replication	10
2.1.4 Genetic diversity of HIV	12
2.1.5 HIV nomenclature system	14
2.2 Molecular Epidemiology of HIV	17

## TABLE OF CONTENTS

	<b>Page</b>
2.2.1 The global epidemiology of HIV	17
2.2.2 HIV-1 subtype and CRF in pandemic	23
2.2.3 The HIV epidemic in South, Southeast Asia and China	26
2.2.4 The HIV epidemic in Thailand	31
2.3 Genetic subtype screening assay	33
2.3.1 The heteroduplex mobility assay (HMA)	33
2.3.2 Subtype specific PCR assay	33
2.3.3 V3-loop peptide enzyme linked immunosorbent assay (V3-PEIA)	34
2.3.4 The Multi-region Hybridization Assay (MHA)	34
2.4 Full-length genome PCR amplification and DNA sequencing	35

## CHAPTER 3 RESEARCH DESIGN, MATERIALS AND METHODS

3.1 Research design	36
3.2 Materials and Methods	37
3.2.1 Samples collection	37
3.2.1.1 Prevalence study	37
3.2.1.2 Incidence study	38
3.2.2 Samples preparation	40

## TABLE OF CONTENTS

	<b>Page</b>
3.2.2.1 Peripheral blood mononuclear cell (PBMC) isolation	40
3.2.2.2 Extraction of genomic DNA	41
3.2.2.3 Extraction of RNA	43
3.2.3 The Multi-region Subtype Specific PCR (MSSP) assay development	45
3.2.3.1 Multiple alignment of reference HIV-1 genome sequences	45
3.2.3.2 Primer design	46
3.2.4 The MSSP assay	48
3.2.4.1 DNA MSSP development	50
3.2.4.2 MSSP evaluation	51
3.2.4.3 Reverse Transcription MSSP	51
3.2.5 Data Analysis	52

## CHAPTER 4 RESULTS

4.1 Design and evaluation of subtype-specific primers	53
4.2 The initial evaluation of the assay (sensitivity and subtype specificity)	62
4.3 MSSP assay evaluation on clinical samples	70

## TABLE OF CONTENTS

	<b>Page</b>
4.4 Performance of Reverse Transcription MSSP assay on clinical samples	76
4.5 Reverse Transcription MSSP assay and dual infections	81
4.6 Verification of subtype B specific PCR products in <i>Pol</i> <i>RT</i> region	84
4.7 HIV-1 subtype distribution and socio/demographic characteristics of drug users in northern Thailand	87
<b>CHAPTER 5 DISCUSSION AND CONCLUSION</b>	<b>89</b>
<b>REFERENCES</b>	<b>95</b>
<b>APPENDICES</b>	
<b>APPENDIX A:</b> Results of RT-MSSP assay in serum samples from Thailand in each genome region	114
<b>APPENDIX B:</b> Equipments	139
<b>APPENDIX C:</b> Supplies	141
<b>APPENDIX D:</b> Chemicals and reagents	142
<b>APPENDIX E:</b> Reagent preparations	144



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright © by Chiang Mai University  
All rights reserved

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
2.1	Global summary of the HIV/AIDS epidemic in December 2004	18
2.2	HIV and AIDS estimates in South, Southeast Asia, end 2004	27
2.3	HIV and AIDS estimates in Myanmar, end 2003	28
2.4	HIV and AIDS estimates in China, end 2003	30
4.1	Primers used in the MSSP Assay for CRF01_AE, subtype B, and subtype C	54
4.2	The results of MSSP assay on a panel of 41 clinical DNA samples	71
4.3	Sensitivity and specificity of primers in MSSP assay	75
4.4	Reactivity of primers in drug users cohort using the Reverse Transcription MSSP assay	78
4.5	The results of Reverse Transcription MSSP assay in samples with dual infections	83
4.6	HIV-1 subtype distribution among drug users cohort in Northern Thailand, 1999-2000	88


## LIST OF FIGURES

<b>Figure</b>	<b>Page</b>
2.1 The structure of Human Immunodeficiency Virus (HIV)	6
2.2 HIV-1 genomic structures	9
2.3 HIV-1 replication cycle	11
2.4 The mechanism of HIV recombination	13
2.5 An example of Circulating Recombination Form (CRF)	16
2.6 Global estimates for adults and children, end 2004	19
2.7 Adults and children estimated to be living with HIV/AIDS, end 2004	20
2.8 Estimated number of adults and children newly infected with HIV during 2004	21
2.9 Estimated adults and children deaths due to HIV/AIDS during 2004	22
2.10 Phylogenetic tree of HIV-1 group M	24
2.11 Global Distribution of HIV-1 subtypes and recombinants	25
3.1 Phylogenetic tree of the panel used	39
3.2 Localization of MSSP primers in prototypic HIV-1 strains circulating in South East Asia	47
3.3 MSSP assay layout	49
4.1 The result of initial evaluation of the MSSP assay in each region of HIV genome	63

Figure	Page
4.2 MSSP assay evaluation with reference strains using subtype specific CRF01_AE primers in <i>Gag</i> , <i>Pol PR</i> , <i>Pol RT</i> , and <i>Pol IN</i> region	64
4.3 MSSP assay evaluation with reference strains using subtype specific CRF01_AE primers in <i>Vpr</i> , <i>Gp120</i> , <i>Rev</i> , and <i>Nef</i> region	65
4.4 MSSP assay evaluation with reference strains using subtype specific B primers in <i>Gag</i> , <i>Pol PR</i> , <i>Pol RT</i> , and <i>Pol IN</i> region	66
4.5 MSSP assay evaluation with reference strains using subtype specific B primers in <i>Vpr</i> , <i>Gp120</i> , <i>Rev</i> , and <i>Nef</i> region	67
4.6 MSSP assay evaluation with reference strains using subtype specific C primers in <i>Gag</i> , <i>Pol PR</i> , <i>Pol RT</i> , and <i>Pol IN</i> region	68
4.7 MSSP assay evaluation with reference strains using subtype specific C primers in <i>Vpr</i> , <i>Gp120</i> , <i>Rev</i> , and <i>Nef</i> region	69
4.8 The performance of the MSSP assay on the genome structure of 41 clinical DNA samples	73
4.9 Sensitivity of the MSSP assay on the panel of 41 clinical DNA samples in each region	74
4.10 Reactivity of Reverse Transcription-MSSP assay on 337 serum samples in each region	77
4.11 Percentage of sample typed by number of typeable region	79
4.12 Percentage of typable samples by number of typeable region	80



<b>Figure</b>	<b>Page</b>
4.13 HIV-1 subtype distribution in drug user cohort	82
4.14 Gel picture of subtype B in <i>Pol RT</i> region	85
4.15 DNA sequences of subtype B in <i>Pol RT</i> region	86



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright © by Chiang Mai University  
All rights reserved

## ABBREVIATIONS AND SYMBOLS

AIDS	Acquired Immunodeficiency Syndrome
CA	Capsid protein
CD	Cluster of differentiation
CRFs	Circulating recombinant forms
CSWs	Commercial sex workers
DNA	Deoxyribonucleic acid
dATP	Deoxyadenosine triphosphate
dCTP	Deoxycytidine triphosphate
dGTP	Deoxyguanosine triphosphate
dTTP	Deoxythymidine triphosphate
dNTP	Deoxyribonucleoside triphosphate
dsDNA	Double-stranded DNA
EIA	Enzyme-linked immunosorbent assay
ER	Endoplasmic reticulum
ENV	Envelope
G	Gravity
GAG	Group specific antigens
Gp	Glycoprotein
HIV	Human Immunodeficiency Virus
HLA	Human leukocyte antigens
HMA	Heteroduplex mobility assay

IDU	Injecting drug users
IN	Integrase
K3-EDTA	Tri-potassium ethylenediaminetetraacetic acid
kb	Kilobase
kcal	Kilocalory
LTR	Long terminal repeat
MA	Matrix protein
MHA	Multi-region Hybridization Assay
MHC	Major histocompatibility complex
Min	Minute
ml	Milliliter
mM	Millimolar
MSSP	Multi-region subtype specific PCR
nM	Nanomolar
NC	Nucleocapsid protein
NDTC	Northern Drug Treatment Center
NEF	Negative factor
OR	Odds ratio
PBMC	Peripheral blood mononuclear cell
PCR	Polymerase chain reaction
POL	Polymerase
PR	Protease
REV	Regulatory factor for HIV expression
RFLP	Restriction fragment length polymorphism

RNA	Ribonucleic acid
rpm	Round per minute
RT	Reverse transcriptase
Sec	Second
TAT	Transactivator of transcription
T <sub>m</sub>	Melting temperature
U	Unit
μg	Microgram
μl	Microliter
μM	Micromolar
UNAIDS	The Joint United Nations Programme on HIV/AIDS
URF	Unique recombinant form
USA	United States of America
V3-PEIA	V3- loop peptide enzyme-linked immunosorbent assay
VIF	Viral infectivity factor
VPR	Viral protein R
VPU	Viral protein U
WHO	World Health Organization
°C	Degree Celsius
%	Percent
Δ	Delta